3.05

2.24% -0.07

Altimmune Inc (ALT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$3.12

Offen:

$3.12

24-Stunden-Volumen:

2.99M

Relative Volume:

0.71

Marktkapitalisierung:

$593.15M

Einnahmen:

$36,000

Nettoeinkommen (Verlust:

$-91.08M

KGV:

-3.253

EPS:

-0.9376

Netto-Cashflow:

$-71.67M

1W Leistung:

-3.48%

1M Leistung:

+16.86%

6M Leistung:

-24.13%

1J Leistung:

-30.68%

1-Tages-Spanne:

$2.95

$3.135

1-Wochen-Bereich:

$2.93

$3.30

52-Wochen-Spanne:

$2.56

$6.4399

Altimmune Inc Stock (ALT) Company Profile

Firmenname

Altimmune Inc

Sektor

Healthcare (1096)

Branche

Biotechnology (616)

Telefon

(240) 654-1450

Adresse

910 CLOPPER ROAD, GAITHERSBURG, MD

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-08-11

Neueste SEC-Einreichungen

ALT's Discussions on Twitter

Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ALT Altimmune Inc	3.05	593.15M	36,000	-91.08M	-71.67M	-0.9376
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-04-24	Hochstufung	Goldman	Sell → Neutral
2026-03-18	Eingeleitet	Truist	Buy
2026-01-28	Eingeleitet	Barclays	Overweight
2025-07-10	Fortgesetzt	Goldman	Sell
2025-02-28	Eingeleitet	William Blair	Mkt Perform
2025-01-08	Eingeleitet	Stifel	Buy
2024-11-12	Eingeleitet	UBS	Buy
2024-04-29	Herabstufung	Guggenheim	Buy → Neutral
2024-01-24	Eingeleitet	Goldman	Neutral
2023-03-22	Herabstufung	Goldman	Buy → Neutral
2022-12-01	Eingeleitet	Goldman	Buy
2021-12-29	Fortgesetzt	Jefferies	Buy
2021-06-02	Eingeleitet	H.C. Wainwright	Buy
2021-02-11	Eingeleitet	Guggenheim	Buy
2020-12-14	Eingeleitet	Jefferies	Buy
2020-11-12	Bestätigt	B. Riley Securities	Buy
2020-09-25	Eingeleitet	B. Riley FBR	Buy
2020-08-14	Eingeleitet	Evercore ISI	Outperform
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-07-28	Eingeleitet	JMP Securities	Mkt Outperform
2020-02-24	Fortgesetzt	ROTH Capital	Buy
2019-07-19	Eingeleitet	ROTH Capital	Buy
2017-10-09	Eingeleitet	Piper Jaffray	Overweight

Alle ansehen

Altimmune Inc Aktie (ALT) Neueste Nachrichten

Jul 09, 2026

Altimmune advances research to address alcohol use disorder and liver disease link - Traders Union

Jul 09, 2026

LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits

Jul 09, 2026

Altimmune, Inc. Actuals & Estimates (DUS:3G0) - TradingView

Jul 09, 2026

Jul 07, 2026

Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing CatalystUpgrade (ALT) - Seeking Alpha

Jul 07, 2026

Here's why you should add Altimmune stock to your portfolio now - MSN

Jul 07, 2026

Jul 05, 2026

Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market - Yahoo Finance

Jul 05, 2026

Jul 04, 2026

5 Overlooked Penny Stocks to Buy Right Now - Insider Monkey

Jul 04, 2026

ETFs Investing in Altimmune, Inc. Stocks - TradingView

Jul 04, 2026

Jun 30, 2026

ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits

Jun 30, 2026

ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits

Jun 30, 2026

Medicare Obesity Drug Coverage Puts These 3 Biotech Stocks In Focus - Sahm

Jun 30, 2026

Jun 29, 2026

VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits

Jun 29, 2026

Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2000 Value Benchmark - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index - marketscreener.com

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark - marketscreener.com

Jun 29, 2026

ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review

Jun 29, 2026

Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 3000E Growth Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

ALT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review

Jun 28, 2026

ALT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Annou - The National Law Review

Jun 28, 2026

Altimmune, Inc.(NasdaqGM: ALT) added to Russell 2500 Value Benchmark - marketscreener.com

Jun 28, 2026

Jun 27, 2026

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits

Jun 27, 2026

Price to book forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 27, 2026

Price to book forward of Altimmune, Inc. – SWB:3G0 - TradingView

Jun 27, 2026

Enterprise value to revenue forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 27, 2026

Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker - The Globe and Mail

Jun 26, 2026

Price to earnings forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Price to sales forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Altimmune, Inc. Actuals & Estimates (NASDAQ:ALT) - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Altimmune, Inc. – BMV:ALT1 - TradingView

Jun 26, 2026

Jun 25, 2026

Enterprise value to EBITDA forward of Altimmune, Inc. – NASDAQ:ALT - TradingView

Jun 25, 2026

ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN

Jun 25, 2026

ALT Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

A2N5Z6 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 24, 2026

Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20? - Insider Monkey

Jun 24, 2026

Is Altimmune worth buying ahead of 2026 catalysts? - MSN

Jun 24, 2026

Jun 23, 2026